Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Colin Lindsay
colin.lindsay1@nhs.net


Dr Revolution Medicines Study Director
medinfo@revmed.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Phase III study of daraxonrasib (RMC-6236) in previously treated NSCLC patients with RAS mutations
Back

Phase III study of daraxonrasib (RMC-6236) in previously treated NSCLC patients with RAS mutations

Recruiting

Open to: All Genders

Age: Adult

$location.addressLine3

Medical Conditions

RAS mutant non-small cell lung cancer

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The aim of this study is to compare the effects of daraxonrasib versus docetaxel in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with a mutation in the RAS oncogene.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

07 May 2025 01 Jan 2027

There will be a pre-screening period up to 14 days during which study doctors will see if the patient’s tumor has a RAS mutation. This is followed by a screening period up to 28 days (when patients meet with study doctors and undergo tests to see if they can join the study). This is followed by a treatment period and a follow-up period. During the treatment period, half of the patients will receive daraxonrasib and the other half will receive docetaxel. This is followed by a treatment period and a follow-up period.


Patients aged 18 years and over with NSCLC with a RAS mutation

You can take part if:



You may not be able to take part if:


1. Prior therapy with any direct RAS-targeted therapy or docetaxel2. Untreated central nervous system (CNS) metastases3. Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function)4. Ongoing anticancer therapy5. Pregnant or breastfeeding6. Other driver mutations for which an approved targeted therapy is available

For the full list of exclusion criteria, please refer to the protocol


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

Docetaxel is an approved drug commonly used to treat patients with NSCLC and the side effects are well-known. Daraxonrasib is currently being investigated in ongoing clinical studies; therefore, all the possible side effects are not fully known at this time. As with any drug, an allergic reaction can occur after taking or receiving any study treatment. Allergic reactions can be mild or more serious and can even result in death. Common symptoms of an allergic reaction are rash, itching, skin problems, swelling of the face and throat, or breathing difficulties.
Daraxonrasib may have some or all of the side effects listed in this section. It is also possible that they might have other side effects that are not listed in the table below. As with any experimental drug, unknown and potentially serious or life-threatening side effects could occur from the study treatment you may receive during the study. Once the study drug(s) is/are stopped, it is not known how long the side effects will last.
The following are the most common side effects (may affect more than 1 in 10 people) that have been reported in the clinical trial for patients taking daraxonrasib monotherapy (daraxonrasib alone): rash, nausea/vomiting, fatigue (feeling tired)/loss of energy or strength, diarrhoea, constipation, scaliness or thickening of the skin, painful inflammation and/or sores in the mouth and gums, effects on the kidneys and urinary tract, including protein in the urine or changes in the salts in the blood, inflammation of the liver and/or abnormal blood tests, and decrease in red blood cells (cells that carry energy and oxygen in the blood).
The most common side effects reported with docetaxel are: infections, decrease in white blood cells (with or without fever), decrease in red blood cells, exaggerated response by the immune system to the drug, low number of platelets (which may cause bleeding and bruising),
damage to the nerves (which can cause numbness, pain, and weakness), taste disorder, shortness of breath, constipation, loss of appetite, nail disorders, fluid retention, feeling weak, joint and muscle pain, nausea, diarrhoea, vomiting, mouth sores, hair loss, skin reactions, and muscle aches.
The following serious and/or severe side effects have been reported with docetaxel: second cancer, skin reactions (redness of hands and feet with swelling followed by peeling), nervous system reactions (tingling/numbness, intense sensation, and pain), eye disorders (retina swelling), feeling weak, unborn baby toxicity, and tumour lysis syndrome (breakdown/death of tumour cells releases cell contents into the blood, causing damage to organs).
Allergic reactions to the radioactive tracer are rare but could occur. Occasionally, some soreness or swelling may develop at the injection site. These symptoms can usually be relieved by applying moist, warm compresses to your arm. There is always a slight risk of damage to cells or tissue from being exposed to any radiation, including the low level of radiation released by the radioactive tracer used for this test.
As part of the CT scans, you will be given a radioactive contrast dye by mouth and/or by an injection through your vein, which will expose you to a small amount of radiation. A person who has allergies is more likely to have an allergic reaction to the dye. This reaction may be mild, such as a skin rash or hives, or severe, such as breathing difficulties or shock.
An MRI scan uses radio waves and a strong magnetic field to provide images of internal organs and tissues. Because an MRI scanner uses strong magnets, you cannot have any metal implants in your body when you have an MRI
They may feel some amount of pain or discomfort during the biopsy, including pain when a local anesthetic is injected by needle to numb the area, pressure and pain where the biopsy needle is inserted, discomfort from lying still for a long time, and soreness at the biopsy site. Although not common, there is a risk of abnormal wound healing, bleeding, damage to nearby tissues or organs, fever, infection, and allergic reaction to the anesthetic.
Taking blood from a vein (usually in the arm) may cause local pain, bruising, occasional light-headedness, fainting, and very rarely, infection at the site of the blood draw. A small hollow plastic catheter may be placed in the vein on days when for blood sample collection on days when frequent sampling is required.

Dr Revolution Medicines Study Director
medinfo@revmed.com


Dr Colin Lindsay
colin.lindsay1@nhs.net



The study is sponsored by Revolution Medicines (United States) and funded by Revolution Medicines.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN17936325
Last updated 05 November 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top